Importance of Gabapentin Dose in Treatment of Opioid Withdrawal
The DOI matches its Crossref record.
Abstract
AIM: The aim of the study was to evaluate the efficacy of gabapentin (1600 mg/d) as an adjunctive to methadone-assisted detoxification in the treatment of opioid withdrawal symptoms. DESIGN: This was a 3-week open-label study (as second phase) following a double-blind, placebo-controlled study with 900 mg/d of gabapentin (as first phase of this study). SETTING: The study was conducted at a specialized outpatient clinic for the treatment of patients with addictive disorders. PARTICIPANTS: The study subjects were composed of 27 patients addicted to opiate who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for opioid dependency, randomly selected among outpatients referred to our clinic. INTERVENTION: Subjects received adjunctive treatment with gabapentin (1600 mg/d) in addition to methadone-assisted detoxification for 3 weeks. MEASUREMENTS: Subjective Opiate Withdrawal Scale (SOWS) with a total score of 0 to 64 was administered at 6 time points during the study. FINDINGS: The total SOWS score was significantly decreased after the intervention. Compared to our previous trial, an almost significant difference was observed in total SOWS scores between groups treated with gabapentin 1600 and 900 mg/d at the end of the intervention period (P = 0.06). Gabapentin with a dose of 1600 mg/d was significantly superior to a dose of 900 mg/d in decreasing severity of coldness, diarrhea, dysphoria, yawing, and muscle tension. CONCLUSIONS: Add-on gabapentin with a dose of 1600 mg/d is effective in reducing some of the withdrawal symptoms in patients addicted to opiate undergoing methadone-assisted detoxification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
“Studies evaluating two doses of gabapentin found greater efficacy associated with the higher dose (1200, 1600, 1800 mg/d) relative to the lower dose studied (900 mg/d) [44,72,80], lending further support to the likelihood of a true pharmacological effect of gabapentin on study outcomes.”
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity
Toce, M. S., Chai, P. R., Burns, M. M., & Boyer, E. W. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0685-1 · Cited by 90
Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine
Reeves, R. R., & Ladner, M. E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111526 · Cited by 43
Metadata
- Authors
- Salehi, M., Kheirabadi, G. R., Maracy, M. R., & Ranjkesh, M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-10
- Volume
- 31
- Issue
- 5
- Pages
- 593-596
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2008496020
- Cited by
- 69
- References
- 0
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Importance of Gabapentin Dose in Treatment of Opioid Withdrawal. https://app.cochat.ai/papers/10.1097/jcp.0b013e31822bb378
- The paper
- Salehi, M., Kheirabadi, G. R., Maracy, M. R., & Ranjkesh, M. (2011). Importance of Gabapentin Dose in Treatment of Opioid Withdrawal. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31822bb378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.